ABVC BioPharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on May 9, 2024, by ABVC BioPharma, Inc. (ABVC), a Nevada corporation listed on The Nasdaq Stock Market LLC. The report discloses the entry into a material definitive agreement on May 8, 2024, with OncoX BioPharma, Inc. ("OncoX"), a private company registered in the British Virgin Islands.
Key Financial Metrics and Transaction Details
The filing details a licensing agreement rather than standard periodic financial results. Key financial terms of the agreement include:
- Total Consideration: $6,250,000 payable within 30 days of the agreement date.
- Payment Structure: Payment may be made in cash or via 1,250,000 OncoX shares valued at $5 per share (based on private negotiation).
- Milestone Payment: An additional $625,000 in cash is due after OncoX's next round of fundraising, which is not guaranteed.
- Installment Option: OncoX may remit cash payments of at least $100,000 toward licensing fees, deductible from the second milestone.
- Royalties: ABVC is entitled to 5% of Net Sales from the first commercial sale of the Licensed Product in the specified territory.
The filing text does not provide clear values for ABVC's current revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes and Agreement Scope
The material change is the execution of the "OncoX Agreement," granting OncoX an exclusive right to develop and commercialize ABVC's BLEX 404 single-herb botanical drug extract (derived from Maitake Mushroom) for the treatment of Pancreatic Cancer. The territory covers 50% of Worldwide Markets for a term of 20 years. A similar agreement was simultaneously entered into with ABVC's affiliate, Rgene Corporation.
Outlook, Risks, and Contingencies
Management commentary highlights several uncertainties and risks associated with the transaction:
- Fundraising Risk: The $625,000 milestone payment is contingent upon OncoX completing a future fundraising round, which cannot be guaranteed.
- Commercialization Risk: The receipt of royalties is contingent on the first commercial sale of the Licensed Product, which remains uncertain.
- Valuation Note: The share price of $5 used for the consideration calculation was determined through private negotiations; no third-party valuation was completed.
- Regulatory Status: The securities mentioned in the agreement have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the financial stability and fundraising capabilities of OncoX BioPharma, Inc. to assess the likelihood of the $625,000 milestone payment.
- Review the full text of the Definitive License Agreement (Exhibit 10.1) for specific definitions of "Net Sales" and territory exclusions.
- Confirm the regulatory status of BLEX 404 and the timeline for potential commercialization to evaluate royalty potential.
- Investigate the relationship and financial standing of the affiliate, Rgene Corporation, regarding the parallel agreement.
- Monitor future filings for updates on the receipt of the initial $6,250,000 consideration and any subsequent fundraising by OncoX.